Precision drug, antibody and radiation therapy kills tumours
Scientists have found a way to combine a precision drug therapy with an antibody and radiation to eliminate tumours without causing side effects.
“This is a one-two punch,” said Charly Craik, Professor of Pharmaceutical Chemistry at University of California, San Francisco (UCSF) and co-senior author of the study. “We could potentially kill the tumours before they can develop resistance.”
The project began 10 years ago when UCSF’s Professor Kevan Shokat discovered how to attack KRAS, a cancer-causing protein. The research led to the development of drugs that latched onto cancerous KRAS, but the drugs could only shrink tumours for a few months before the cancer came back.
In 2022, a UCSF team that included Craik and Shokat demonstrated that the KRAS drugs could be used as permanent flags for cancer cells. They also designed an antibody that recognised the unique drug/KRAS surface fragment and beckoned to immune cells.
Around the same time, Craik began working with Mike Evans, Professor of Radiology at UCSF, to develop an approach that armed the antibodies with radioactive payloads.
Craik said: “The beauty of this approach is that we can calculate an extremely safe dose of radiation. Unlike external beam radiation, this method uses only the amount of radiation needed to beat the cancer.”
Building on the work, Kliment Verba, Assistant Professor of Cellular and Molecular Pharmacology at UCSF, is using cryo-electron microscopy to visualise the ‘radiation sandwich’ in atomic detail, giving the field a structure to develop even better antibodies.
“The drug bound to the KRAS peptide sticks out like a sore thumb, which the antibody then grabs,” said Verba. “We’ve taken a significant step toward patient-specific radiation therapies, which could lead to a new paradigm for treatment.”
Diana Spencer, Senior Digital Content Editor, DDW
